For the quarter ending 2026-03-31, INTS had -$6,153K decrease in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Net loss | 6,121 | -2,671 | -5,884 |
| Change in carrying value of right-of-use asset | -12 | 6 | 13 |
| Stock-based compensation expense | -1,163 | 471 | 1,079 |
| Stock issued in exchange for services | - | 0 | - |
| Accrued interest on marketable debt securities | - | 0 | 0 |
| Prepaid expenses, other current assets, and other assets | -471 | 297 | 47 |
| Accounts payable, accrued expenses and other liabilities | -411 | 104 | 394 |
| Net cash used in operating activities | 5,006 | -2,387 | -4,445 |
| Purchase of marketable debt securities | - | 0 | 0 |
| Redemption of marketable debt securities | - | 0 | 0 |
| Net cash provided by investing activities | - | 0 | 0 |
| Proceeds from exercise of warrants and options | - | 0 | 0 |
| Proceeds from public offerings | - | 0 | 4,652 |
| Proceeds from atm offerings and common stock issuances-Common Stock Issuances | - | 0 | 24 |
| Issuance costs related to public offerings and atm offering-Public Offering | - | 0 | 933 |
| Proceeds from atm offerings | -7,727 | 7,539 | 345 |
| Issuance costs related to atm offerings | -311 | 301 | 17 |
| Net cash provided by financing activities | -11,159 | 7,238 | 4,071 |
| Net decrease in cash and cash equivalents | -6,153 | 4,851 | -374 |
| Cash and cash equivalents at beginning of period | 7,067 | 2,590 | - |
| Cash and cash equivalents at end of period | 10,245 | 7,067 | - |
INTENSITY THERAPEUTICS, INC. (INTS)
INTENSITY THERAPEUTICS, INC. (INTS)